A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma Patients

Combination therapy with RAS inhibitors shows promise for pancreatic cancer regression and resistance prevention

Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates. Recent studies using RAS inhibitors have opened the doo

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM

Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊

First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know

Jun 1, 2026 - By Erin Post NEW — Additional Data on Daraxonrasib Released: “Significant Advances” for Pancreatic Cancer Treatment Daraxonras

PanCAN Statement on Positive Overall Survival Results from Revolution Medicines Phase III Trial at ASCO

Jun 1, 2026 - By Julie Vasquez The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress again

Research Spotlight: A New Era of Progress Against Pancreatic Cancer

May 27, 2026 - By Anna Berkenblit, MD, MMSc Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit , PanCAN’s Chie

<![CDATA[EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process]]>